Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$195.9m

Anika Therapeutics Past Earnings Performance

Past criteria checks 0/6

Anika Therapeutics has been growing earnings at an average annual rate of 6.2%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 6.6% per year.

Key information

6.18%

Earnings growth rate

6.26%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-6.56%
Return on equity-8.27%
Net Margin-9.53%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Apr 30

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Summary Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK’s Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks. ANIK’s valuation seems quite cheap overall, with no financial debt and positive TTM cash flows. So, despite its inherent regulatory and execution risks, I remain bullish. Read the full article on Seeking Alpha
Analysis Article • Aug 06

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive

NasdaqGS:ANIK 1 Year Share Price vs Fair Value Explore Anika Therapeutics's Fair Values from the Community and select...
Analysis Article • May 10

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price

Anika Therapeutics, Inc.'s ( NASDAQ:ANIK ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy...
Analysis Article • Dec 19

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 1.4x Anika Therapeutics, Inc. ( NASDAQ:ANIK ) may be sending very bullish...
Analysis Article • Jan 30

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Key Insights Anika Therapeutics' estimated fair value is US$44.70 based on 2 Stage Free Cash Flow to Equity Anika...
Analysis Article • Aug 03

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 11

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics' share price is being punished by the market owing to some possibly over-ambitious growth projections made in June last year. Management believed it could nearly double revenues, to $230m, by 2024, but after a so-so 2021, these plans have been abandoned. Anika is attempting to pivot from pain management and its Monovisc and Orthovisc injectables, to joint preservation, having acquired two businesses in 2020. Progress has not been bad - Anika is growing revenues, is profitable, and has nearly $100m cash - but it hasn't been as good as promised. I'm not entirely sure about Anika's long-term prospects, since it's moving away from its core revenues generating business into a new field, but I do think the market undervalues the business at current market cap of ~$350m.
Analysis Article • Jun 25

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Today we will run through one way of estimating the intrinsic value of Anika Therapeutics, Inc. ( NASDAQ:ANIK ) by...
Analysis Article • Mar 16

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Revenue & Expenses Breakdown

How Anika Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ANIK Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26116-115426
31 Dec 25113-104926
30 Sep 25113-144826
30 Jun 25115-135025
31 Mar 25117-115325
31 Dec 24120-95626
30 Sep 2486102916
30 Jun 249854018
31 Mar 2411254820
31 Dec 23121-36022
30 Sep 23163-259933
30 Jun 23162-229532
31 Mar 23157-229330
31 Dec 2211425118
30 Sep 22152-168226
30 Jun 22152-117826
31 Mar 22150-27527
31 Dec 2114847427
30 Sep 21145-67028
30 Jun 21137-136925
31 Mar 21129-276322
31 Dec 20130-245722
30 Sep 20128-45020
30 Jun 20126114019
31 Mar 20125283618
31 Dec 19115273517
30 Sep 19112313117
30 Jun 19109292717
31 Mar 19109302617
31 Dec 18106192818
30 Sep 18108192718
30 Jun 18108182820
31 Mar 18111202620
31 Dec 17113322219
30 Sep 17113322017
30 Jun 17111342014
31 Mar 17104311913
31 Dec 16103331811
30 Sep 16106361710
30 Jun 1610335169
31 Mar 1610034158
31 Dec 159331158
30 Sep 158528148
30 Jun 158425158

Quality Earnings: ANIK is currently unprofitable.

Growing Profit Margin: ANIK is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ANIK is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.

Accelerating Growth: Unable to compare ANIK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANIK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: ANIK has a negative Return on Equity (-8.27%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 15:17
End of Day Share Price 2026/06/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anika Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Anderson SchockB. Riley Securities, Inc.
Mark LandyNorthland Capital Markets